Skip to content

Arena Pharmaceuticals Announces Poster at the American Heart Association (AHA) Scientific Sessions 2016

Press Release

Arena Pharmaceuticals Announces Poster at the American Heart Association (AHA) Scientific Sessions 2016

SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Professor Lucie Clapp will present a poster at the American Heart Association (AHA) Scientific Sessions 2016 on Monday, November 14 at 10:45am CT.  The scientific sessions are taking place November 12-16, 2016 in New Orleans, Louisiana at the Ernest N. Morial Convention Center.

The following poster will be presented:

APD811, a Novel and Highly Selective Non-prostanoid IP Receptor Agonist in Smooth Muscle Cells From Patients With Pulmonary Hypertension

Session Type: Abstract Poster Session
Session Number: VA.APS.P189
Poster Session:  Novel Mechanisms of Pulmonary Vascular Disease
Date: Monday, November 14, 2016, 10:45 am - 12:00 noon
Location:  Ernest N. Morial Convention Center, Science and Technology Hall-Clinical Science Section

About Arena Pharmaceuticals
We are a biopharmaceutical company focused on developing novel, small molecule drugs across a range of therapeutic areas.  We have three primary proprietary investigational clinical programs: etrasimod (APD334) in Phase 2 evaluation for ulcerative colitis, APD371 entering Phase 2 evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH).  Additionally, we have collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences Ltd. (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Our US operations are located in San Diego, California. Our primary clinical operations are located in Zug, Switzerland, and our commercial manufacturing for BELVIQ is located in Zofingen, Switzerland.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the upcoming presentation; and Arena's focus, primary programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc.                                                        
Kevin R. Lind, Chief Financial Officer      

Arena Pharmaceuticals Logo

Logo -


To view the original version on PR Newswire, visit:

SOURCE Arena Pharmaceuticals, Inc.

News Provided by Acquire Media